


Dapagliflozin improves glucose outcomes in type 1 diabetes

26 April 2019



(HealthDay)—In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in *Diabetes Care*.

Chantal Mathieu, M.D., PhD., from the University of Leuven in Belgium, and colleagues assessed continuous [glucose](#) monitoring in patients with inadequately controlled type 1 diabetes (hemoglobin A1c [HbA1c] ≥ 7.7 to ≤ 11 percent) who received dapagliflozin as an adjunct to adjustable insulin as part of two phase 3 clinical trials. Pooled data included 1,591 patients receiving dapagliflozin 5 mg (530 patients), dapagliflozin 10 mg (529), or placebo (532).

The researchers found that patients receiving dapagliflozin (either dose) spent more time with HbA1c in the range of >3.9 to ≤ 10 mmol/L for 24 hours than those receiving placebo. From baseline to week 24, the adjusted mean change was 6.48 percent with dapagliflozin 5 mg, 8.08 percent with

dapagliflozin 10 mg, and ≥ 2.59 percent with placebo. The mean amplitude of glucose excursion over 24 hours, mean 24-hour glucose values, and postprandial glucose values at week 24 also improved in [patients](#) receiving dapagliflozin versus placebo. However, there were no substantial differences at week 24 between dapagliflozin 5 or 10 mg and placebo with regard to the percentage of glucose values ≥ 3.9 mmol/L or ≥ 3 mmol/L for 24 hours or nocturnal glucose values ≥ 3.9 mmol/L.

"The reduced variability reported here suggests that treatment with dapagliflozin along with adjustable insulin may improve treatment adherence and reduce the risk of complications in people with type 1 diabetes," the authors write.

Several authors disclosed financial ties to [medical device](#) and [pharmaceutical companies](#), including AstraZeneca, which manufactures dapagliflozin and supported the study.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

APA citation: Dapagliflozin improves glucose outcomes in type 1 diabetes (2019, April 26) retrieved 28 April 2021 from <https://medicalxpress.com/news/2019-04-dapagliflozin-glucose-outcomes-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.